Free Trial
NASDAQ:LVTX

LAVA Therapeutics Q2 2023 Earnings Report

LAVA Therapeutics logo
$1.25 -0.03 (-2.34%)
Closing price 05/5/2025 03:57 PM Eastern
Extended Trading
$1.21 -0.04 (-3.20%)
As of 05/5/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LAVA Therapeutics EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

LAVA Therapeutics Revenue Results

Actual Revenue
$5.14 million
Expected Revenue
$2.50 million
Beat/Miss
Beat by +$2.64 million
YoY Revenue Growth
N/A

LAVA Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Tuesday, August 22, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

LAVA Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 20, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

LAVA Therapeutics Earnings Headlines

Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year
See More LAVA Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LAVA Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LAVA Therapeutics and other key companies, straight to your email.

About LAVA Therapeutics

LAVA Therapeutics (NASDAQ:LVTX) N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

View LAVA Therapeutics Profile

More Earnings Resources from MarketBeat